RB-120

RB-120

Identifiers
IUPAC name N-{(S)-2-benzyl-3[(S)-(2-amino-4-methylthio)butyldithio]-1-oxopropyl}-l-alanine benzyl ester
PubChem CID	54470354
IUPHAR/BPS	11651
ChEMBL	ChEMBL3299158
CompTox Dashboard (EPA)	DTXSID601336315
Chemical and physical data
Formula	C25H34N2O3S3
Molar mass	506.74 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](C(=O)OCC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)CSSC[C@H](CCSC)N
InChI InChI=1S/C25H34N2O3S3/c1-19(25(29)30-16-21-11-7-4-8-12-21)27-24(28)22(15-20-9-5-3-6-10-20)17-32-33-18-23(26)13-14-31-2/h3-12,19,22-23H,13-18,26H2,1-2H3,(H,27,28)/t19-,22+,23-/m0/s1 Key:XHWYFTNNIZGHRW-PMOQBDJRSA-N

RB-120 (benzyl (2S)-2-{[(2S)-2-({[(2S)-2-amino-4-methylsulfanylbutyl]disulfanyl}methyl)-3-phenylpropanoyl]amino}propanoate) is an orally active analog of the drug RB-101.^[1] It acts as an enkephalinase inhibitor, which is used in scientific research. Via intravenous administration, it is approximately three times as potent as RB-101 or twice as potent as the isolated (S,S) isomer of RB101. However, via i.p. administration it is approximately twice as potent as racemic RB-101 and about as potent as the isolated (S,S) isomer of RB101. During i.v. administration RB120 is approximately twice as weak as morphine in terms of analgesia; however, it is 16x weaker during i.p. and p.o. administration.^[1]

RB 120 produces a significant dose-dependent antinociceptive response in the rat tail-flick test at 10 and 25 min after i.v. administration, at doses of 12.5, 25 and 50 mg/kg.^[1]

The analgesic effect occurred with a slower onset compared to typical IV opioids likely due to the fact that, following enkephalinase inhibition, it may take some time for endogenous enkephalin to accumulate without degradation until sufficient concentration is reached for analgesic effect, whereas for opioids, onset only requires entry into the brain via the blood–brain barrier which occurs rapidly for lipophilic molecules, and binding to the opioid receptor produces a near-instantaneous G-protein mediated response and production of second messenger, without need for de novo synthesis of any neurotransmitters.